A breast cancer vaccine could be closer to reality, according to Cleveland Clinic, as its researchers have announced some encouraging results. Researchers and doctors weigh in.

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Immunology is the study of the immune system and its defense mechanisms, and immuno-oncology is when cancer patients are ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

Patients with lung cancer who have never smoked are usually diagnosed too late for curative treatment. Pam Dalrymple, ...